IL6R and Hepatitis: We found that treatments with IL-6Rα antibodies during the induction of our model significantly diminished hepatitis (p<0.05) as demonstrated by decreased inflammation/injury scores (1.6±0.1, mean ± S.E.)when compared to TFA-S100 – immunized BALB/c mice not treated with this antibody but administered phosphate buffered saline at the same time points (2.3±0.2, mean ± S.E., Fig 10A).